Novartis Bemused As NICE Says No Again To Migraine Drug Aimovig
Executive Summary
The Swiss major is evaluating whether or not there is a case to appeal after the cost watchdog said it is “very uncertain" whether the CGRP inhibitor is more clinically effective for migraine than Botox.
You may also be interested in...
Scottish HTA Body OKs Novartis’ Aimovig For Migraine And Eisai’s Lenvima For Cancer
Scotland’s health technology appraisal body has OKd Novartis’s Aimovig for migraines. England’s NICE has postponed a meeting on the drug after a large number of comments were received following the institute’s initial knockback.
Novartis To Ape Aimovig's US Market Strategy In The EU As CHMP Gives Market Go-Ahead
Swiftly following its first approval in the US, Amgen/Novartis' Aimovig has just been given a CHMP go-ahead in the EU positioning it to be the first CGRP targeting agent on the market there. Launch tactics look set to mirror those in the US.
Pierre Fabre Continues Oncology R&D Push
The French firm has followed up its recent acquisition of Swiss lung cancer specialist Vertical Bio by signing a pact with Vernalis.